Gastrointestinal Submucosal TumorsNCT07353346
Evaluation of Short-term and Long-term Efficacy of Endoscopic Treatment for Gastrointestinal Submucosal Tumors
An observational study of Gastrointestinal Submucosal Tumors, run by Xijing Hospital.
Trial summary
This study aims to comprehensively assess how well endoscopic treatments work for gastrointestinal submucosal tumors (SMTs)-both in the short term right after treatment and over the long run-and to figure out what factors might affect the treatment's success. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Gastrointestinal Submucosal Tumors
- How many people
- 700 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2012to 1 Aug 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who underwent endoscopic treatment for gastrointestinal submucosal tumors at Xijing Hospital from January 1, 2012 to August 1, 2025.
Who may be able to join
- Patients who underwent endoscopic treatment for gastrointestinal submucosal tumors at Xijing Hospital from January 1, 2012 to August 1, 2025.
Who cannot join
- Patients with gastrointestinal protruding lesions caused by external compression.
About this study
This study aims to comprehensively assess how well endoscopic treatments work for gastrointestinal submucosal tumors (SMTs)-both in the short term right after treatment and over the long run-and to figure out what factors might affect the treatment's success. Specifically, it seeks to answer key questions: How effective are common endoscopic procedures at removing these tumors completely? What are the risks of complications like bleeding or perforation after treatment? Do patients stay healthy without the tumor coming back in the years following treatment? And what aspects (such as tumor size, location, or the type of endoscopic method used) influence whether the treatment works well or leads to problems? Study Description and Hypothesis Gastrointestinal submucosal tumors are growths that develop beneath the inner lining of the digestive tract (like the esophagus, stomach, or intestines). Unlike traditional open surgery, endoscopic treatments are minimally invasive-doctors use thin, flexible tubes with cameras and tools to remove tumors through natural body openings, which typically means smaller wounds, faster recovery, and no visible scars. However, there's still limited clear information about how well these treatments hold up over time or which patients benefit most.
This study is a retrospective analysis, meaning researchers will look back at the medical records of 700 patients who received endoscopic treatment for SMTs at Xijing Hospital between January 2012 and August 2025. The team will collect details like the tumor's size and location, the specific endoscopic method used (such as EMR, ESE, STER, or EFR), how long the procedure took, whether any complications occurred, and follow-up results to check for recurrence.
The study's core hypothesis is that endoscopic treatments are safe and effective for gastrointestinal submucosal tumors-successfully removing most tumors with low complication rates-and that factors like the tumor's size, where it's located in the digestive tract, and the type of endoscopic technique used will play a role in how well the treatment works and whether the tumor comes back later. By analyzing these past cases, the research hopes to provide reliable information to help doctors choose the best treatment for patients with SMTs in the future, ensuring more personalized and effective care.
- Conditions
- Gastrointestinal Submucosal Tumors
What is being measured
The primary outcome is the main question the study is designed to answer.
Surgical success rate
The surgical success rate is defined as the operation completion rate
Measured: Three days after the operation
long-term prognosis of patients
long-term prognosis concerns the disease progression at 1 year, 3 years, and 5 years after surgery.
Measured: Taking 1 year, 3 years, and 5 years after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jan 2026
- Study start1 Jan 2012
- Primary completion1 Aug 2025
- Study completion1 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastrointestinal Submucosal TumorsStudies of the same condition, open and under way.
- More trials run by Xijing HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 700 participants (actual)
Sponsor and investigators
- Lead sponsor
- Xijing Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07353346
- Sponsor's protocol ID
- XJLL-KY-20252474
- Status last verified
- Dec 2025
- First submitted
- 25 Dec 2025
- Last updated
- 20 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Short-term and Long-term Efficacy of Endoscopic Treatment for Gastrointestinal Submucosal Tumors
- ClinicalTrials.gov ID
- NCT07353346
- Acronym / sponsor ID
- XJLL-KY-20252474
- Conditions
- Gastrointestinal Submucosal Tumors
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 700 participants (actual)
- Lead sponsor
- Xijing HospitalUniversity, hospital or other
- Study start
- 1 Jan 2012 (actual)
- Primary completion
- 1 Aug 2025 (actual)
- Study completion
- 1 Aug 2025 (actual)
- First posted
- 20 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to comprehensively assess how well endoscopic treatments work for gastrointestinal submucosal tumors (SMTs)-both in the short term right after treatment and over the long run-and to figure out what factors might affect the treatment's success. Specifically, it seeks to answer key questions: How effective are common endoscopic procedures at removing these tumors completely? What are the risks of complications like bleeding or perforation after treatment? Do patients stay healthy without the tumor coming back in the years following treatment? And what aspects (such as tumor size, location, or the type of endoscopic method used) influence whether the treatment works well or leads to problems? Study Description and Hypothesis Gastrointestinal submucosal tumors are growths that develop beneath the inner lining of the digestive tract (like the esophagus, stomach, or intestines). Unlike traditional open surgery, endoscopic treatments are minimally invasive-doctors use thin, flexible tubes with cameras and tools to remove tumors through natural body openings, which typically means smaller wounds, faster recovery, and no visible scars. However, there's still limited clear information about how well these treatments hold up over time or which patients benefit most.
This study is a retrospective analysis, meaning researchers will look back at the medical records of 700 patients who received endoscopic treatment for SMTs at Xijing Hospital between January 2012 and August 2025. The team will collect details like the tumor's size and location, the specific endoscopic method used (such as EMR, ESE, STER, or EFR), how long the procedure took, whether any complications occurred, and follow-up results to check for recurrence.
The study's core hypothesis is that endoscopic treatments are safe and effective for gastrointestinal submucosal tumors-successfully removing most tumors with low complication rates-and that factors like the tumor's size, where it's located in the digestive tract, and the type of endoscopic technique used will play a role in how well the treatment works and whether the tumor comes back later. By analyzing these past cases, the research hopes to provide reliable information to help doctors choose the best treatment for patients with SMTs in the future, ensuring more personalized and effective care.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who underwent endoscopic treatment for gastrointestinal submucosal tumors at Xijing Hospital from January 1, 2012 to August 1, 2025.
Key inclusion criteria (1 listed)
- Patients who underwent endoscopic treatment for gastrointestinal submucosal tumors at Xijing Hospital from January 1, 2012 to August 1, 2025.
Key exclusion criteria (1 listed)
- Patients with gastrointestinal protruding lesions caused by external compression.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Surgical success rate
Time frame: Three days after the operation
The surgical success rate is defined as the operation completion rate
long-term prognosis of patients
Time frame: Taking 1 year, 3 years, and 5 years after surgery
long-term prognosis concerns the disease progression at 1 year, 3 years, and 5 years after surgery.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
Related trials for Gastrointestinal Submucosal Tumors
RecruitingObservational study
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
Superficial Esophageal Cancer, Oesophageal Adenocarcinoma
RecruitingObservational study
Outcomes of Knife-Assisted Full-Thickness Resection for Rectal Lesions: A Multicenter Study
Colorectal Cancer
Recruiting
Epinephrine 1:100,000 Versus 1:500,000 During Gastric Endoscopic Submucosal Dissection
Gastric Neoplasms, Gastric Dysplasia
RecruitingObservational study
Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions
Esophageal Neoplasm, Esophageal Polyp
Active, not recruiting
Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection
Esophageal Squamous Cell Carcinoma (ESCC), High-Grade Intraepithelial Neoplasia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastrointestinal Submucosal Tumors, run by Xijing Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Surgical success rate (time frame: Three days after the operation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.